Recently, Professor Jie Du from Beijing Anzheng Hospital, Capital Medical University was selected into the list of "Top 2% of Global Scientists with Lifetime Scientific Impact 2024". The list selects the scientists with the most "lifetime scientific impact" and "2024 scientific impact" worldwide by modeling and analyzing parameters such as the number of papers published and cited. The list includes the top 2% authors in the global field of cardiovascular science from 1960 to 2023 in the Scopus database. There are 13 experts from China, and Professor Du from Beijing Anzheng Hospital is on the list.
SGC001 is a first-in-class monoclonal antibody indicated for emergency treatment of acute myocardial infarction (AMI). The drug is developed by Professor Zhiwei Sun's team from Sungen Biomedical, in collaboration with Professor Jie Du's team. Till now, there is no antibody therapy for AMI approved for clinical or commercial stage. The successful clinical trial application in China and the US is an important milestone of SGC001. SGC001 has the potential to become a first-in-class drug, providing safer and more effective therapies for AMI patients worldwide.
AMI is a condition characterized by death of myocardia due to acute occlusion of coronary arteries, resulting in high morbidity, mortality, disability rates, as well as serious complications. According to professional epidemiological surveys in China, the mortality of AMI is 2.5 million people per year, and the incidence of AMI reaches millions of patients per year. There is a trend of younger onset of AMI. Findings from prospective PEACE study (Patient-centered Evaluative Assessment of Cardiac Events) published in 2020 suggested that, the number of AMI patients may reach 23 million by 2030 in China. AMI places a significant economic burden on the society and families. According to the Report on Cardiovascular Health and Diseases in China 2022, the total cost of hospitalization for cardiovascular and cerebrovascular diseases in China was 270.901 billion yuan in 2020, with 34.685 billion yuan for AMI. AMI is one of the most important public health problems.
View Original Article：https://elsevier.digitalcommonsdata.com/datasets/btchxktzyw/
Updated: Oct 17, 2024
